No results for ‘’
Zydus Lifesciences Ltd
₹1070.80
(0.34%)
Sat, 20 Jun 2026, 03:12 pm
Health Technology
Pharmaceuticals: Major
24.5KZydus Lifesciences Debt to Equity Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 27.83 | 18.02 | 12.42 | 12.26 | 22.30 | 22.78 | 23.85 | 23.23 | 26.15 | 31.01 | 16.78 | 30.51 | 21.82 | 19.19 | 23.24 | 21.15 | 19.76 | 25.47 | 26.36 | 19.69 |
| Price to book ratio | 6.07 | 4.87 | 3.01 | 3.01 | 6.92 | 7.46 | 6.05 | 5.16 | 6.11 | 8.40 | 5.69 | 6.52 | 4.43 | 3.42 | 2.64 | 3.47 | 2.10 | 2.84 | 5.10 | 3.72 |
| Price to sales ratio | 2.94 | 2.36 | 1.41 | 1.30 | 3.15 | 3.63 | 3.06 | 2.47 | 2.98 | 4.19 | 3.51 | 4.89 | 3.30 | 2.74 | 1.95 | 3.16 | 2.37 | 2.93 | 5.28 | 3.90 |
| Price to cash flow ratio | 38.15 | 16.71 | 17.24 | 16.96 | 17.80 | 25.84 | 41.65 | 33.08 | 27.25 | 36.78 | 16.97 | 34.54 | 44.84 | 12.42 | 10.32 | 14.29 | 17.40 | 18.91 | 30.98 | 12.97 |
| Enterprise value | 4643Cr | 4587Cr | 3969Cr | 4772Cr | 12143Cr | 17048Cr | 17463Cr | 17531Cr | 23253Cr | 37641Cr | 34188Cr | 49148Cr | 42630Cr | 43796Cr | 35446Cr | 50589Cr | 38513Cr | 52094Cr | 103000Cr | 86933Cr |
| Enterprise value to EBITDA ratio | 19.09 | 14.97 | 10.03 | 8.61 | 16.22 | 19.29 | 18.76 | 18.75 | 26.63 | 23.30 | 14.89 | 26.79 | 15.51 | 15.64 | 13.52 | 15.34 | 12.27 | 15.26 | 20.38 | 13.34 |
| Debt to equity ratio | 0.64 | 0.53 | 0.79 | 1.04 | 0.67 | 0.49 | 0.89 | 0.99 | 0.79 | 0.63 | 0.43 | 0.75 | 0.62 | 0.76 | 0.77 | 0.35 | 0.25 | 0.07 | 0.04 | 0.13 |
| Return on equity % | 23.59 | 29.89 | 26.73 | 26.39 | 35.28 | 37.42 | 27.51 | 23.69 | 25.18 | 29.92 | 38.92 | 23.55 | 22.85 | 19.33 | 11.33 | 18.84 | 14.95 | 11.39 | 20.55 | 20.67 |
Zydus Lifesciences Ltd Debt to Equity Ratio
The Zydus Lifesciences Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Zydus Lifesciences Ltd's valuation, profitability, and overall financial performance. Tracking the Zydus Lifesciences Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE, BSE: 532321) is currently trading at ₹1070.80, with a market capitalization of ₹107757.6Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Zydus Lifesciences Ltd Debt to Equity Ratio is essential for fundamental analysis.
Zydus Lifesciences Ltd Debt to Equity Ratio Current Value
The current Zydus Lifesciences Ltd Debt to Equity Ratio stands at 0.13.
The latest Zydus Lifesciences Ltd Debt to Equity Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Zydus Lifesciences Ltd Debt to Equity Ratio Historical Trend
The Zydus Lifesciences Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.13
- 2023: 0.04
- 2022: 0.07
- 2021: 0.25
- 2020: 0.35
The recent rise in Zydus Lifesciences Ltd Debt to Equity Ratio suggests strengthening valuation trends and improving market sentiment.
What Zydus Lifesciences Ltd Debt to Equity Ratio Indicates for Investors
The Zydus Lifesciences Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Zydus Lifesciences Ltd Debt to Equity Ratio Analysis Summary
The Zydus Lifesciences Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Zydus Lifesciences Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Zydus Lifesciences Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.